Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 10, 2007, Pages 725-739

  Choudhary, Shambhunath ^a   Wang, Hwa Chain Robert ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Depsipeptide; HDACI; Pro apoptosis; Ras; Signaling pathway

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FR 901228; HISTONE; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SERINE PROTEINASE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HT29; CONTROLLED STUDY; DEACETYLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACETYLATION; ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASES; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEPSIPEPTIDES; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GENES, RAS; HISTONE DEACETYLASES; HISTONES; HT29 CELLS; HUMANS; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 34548271541     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0213-1     Document Type: Article

References (53)

1. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074
2. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652-658
3. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686
4. Bertram JS (2000) The molecular biology of cancer. Mol Aspects Med 21:167-223
5. Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15:725-731
6. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ (1998) Increasing complexity of Ras signaling. Oncogene 17:1395-1413
7. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 22:469-480
8. Chang MY, Jan MS, Won SJ, Liu HS (1998) Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin. Biochem Biophy Res Commun 248:62-68
9. Chen G, Shu J, Stacey DW (1997) Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. Oncogene 15:1643-1651
10. Coqueret O (2000) New roles of p21 and p27 cell cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13:65-70
11. Daniel JC, Peter HS, John PM, Joel SH, Ursula E, Arthur DL, David VG (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304:507-513
12. de Bruin EC, Meersma D, de Wilde J, den Otter I, Schipper EM, Medema JP, Peltenburg LTC (2003) A serine protease is involved in the initiation of DNA damage-induced apoptosis. Cell Death Diff 10:1204-1212
13. Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293-304
14. Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S, Kohno S (2004) The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3:1397-1402
15. Espino PS, Drobic B, Dunn KL, Davie JR (2005) Histone modifications as a platform for cancer therapy. J Cell Biochem 94:1088-1102
16. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van-Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskosl JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase. J Biol Chem 273:18623-18632
17. Fecteau KA, Mei J, Wang HCR (2002) Differential modulation of signaling pathways and apoptosis of ras-transformed cells by a depsipeptide FR901228. J Pharmacol Exp Ther 300:890-899
18. Grewal SS, Moazed D (2003) Heterochromatin and epigenetic control of gene expression. Science 301:798-802
19. Hoshino R, Tanimura S, Watanabe K, Kataoka T, Kohno M (2001) Blockade of the extracellular singal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated. J Biol Chem 276:2686-2692
20. Huang F, Hsu S, Yan Z, Winawer S, Friedman E (1994) The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras. Oncogene 9:3701-3706
21. Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M,Yasumi T, Watanabe K, Nishikomori R, Nakayama T, Yonehara S, Toguchida J, Nakahata T (2003) FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22:9231-9242
22. Kobayashi Y, Ohtsuki M, Murakami T, Kobayashi T, Sutheesophon K, Kitayama H, Kano Y, Kusano E, Nakagawa H, Furukawa Y (2006) Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 25:512-524
23. Konstantinopoulos PA, Vandoros GP, Papavassiliou AG (2006) FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 58:711-715
24. Marks PA, Miller T, Richon VM. Histone deacetylases (2003) Curr Opin Pharamacol 3:344-351
25. Mendelsohn J, Howley PM, Israel MA, Liotta LA (ed) (2001) The molecular basis of cancer, 2nd edn. W.B. Saunders Company, Philadelphia
26. Nesterov A, Nikrad M, Johnson T, Kraft AS (2004) Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 64:3922-3927
27. O'Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf1. Science 306:2267-2270
28. Piekarz R, Bates S (2004) A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10:2289-2298
29. Puccetti E, Beissert T, Guller S, Li JE, Hoelzer D, Ottmann OG, Ruthardt M (2003) Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene 2:6900-6908
30. Sanchez-Molina S, Oliva JL, Garcia-Vargas S, Valls E, Rojas JM, Martinez-Balbas MA (2006) The histone acetyltransferases CBP/p300 are degraded in NIH 3T3 cells by activation of Ras signalling pathway. Biochem J 398:215-224
31. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE (2000) P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817-825
32. Schulte TW, Blagosklonny MV, Ingui C, Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-24588
33. Sheng H, Shao J, DuBois RN (2001) Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem 276:14498-14504
34. Somwar R, Koterski S, Sweeney G, Sciotti R, Djuric S, Berg C, Trevillyan J, Scherer PE, Rondinone CM, Klip A (2002) A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation. J Biol Chem 277:50386-50395
35. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, Bader P, Beck JF (2006) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766
36. Song P, Wei J, Plummer H, Wang HCR (2004) Potentiated caspase-3 in Ras-transfromed 10T1/2 cells. Biochem Biophys Res Commun 322:557-564
37. Song P, Wang HCR (2004) Efficient identification of tetR-expressing cell lines for tetracyline-regulated gene expression. Electron J Biotechnol 7:210-213
38. Song P, Wei J, Wang HCR (2005) Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228. FEBS Lett 579:90-94
39. Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4:677-685
40. Taddei A, Roche D, Bickmore WA, Almouzni G (2005) The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6:520-524
41. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW (1997) Substrate specificities of caspase family proteases. J Biol Chem 272:9677-9682
42. Trent JC II, McConkey DJ, Loughlin SM, Harbison MT, Fernandez A, Ananthaswamy HN (1996) Ras signaling in tumor necrosis factor-induced apoptosis. EMBO J 15:4497-4505
43. Troppmair J, Rapp UR (2003) Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem Pharmacol 66:1341-1345
44. Tseng YS, Tzeng CC, Chiu AW, Lin CH, Won SJ, Wu IC, Liu HS (2003) Ha-ras overexpression mediated cell apoptosis in the presence of 5-fluorouracil. Exp Cell Res 288:403-414
45. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M (1994a) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 47:301-310
46. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K (1994b) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 47:315-323
47. Vigushin DM (2002) FR-901228 Fujisawa/National Cancer Institute. Curr Opin Investig Drugs 3:1396-1402
48. Viktorsson K, Heiden T, Molin M, Akusjarvi G, Linder S, Shoshan MC (2000) Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin. Apoptosis 5:355-367
49. Wang HCR, Fecteau KA (2000) Detection of a novel quiescence-dependent protein kinase. J Biol Chem 275:25850-25857
50. Wang HG, Rapp UR, Reed JC (1996) Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629-638
51. Watanabe K, Okamoto K, Yonehara S (2005) Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12:10-18
52. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94:504-513
53. Yuan LW, Giordano A (2002) Acetyltransferase machinery conserved in p300/CBP-family proteins. Oncogene 21:2253-2260